Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mallinckrodt PLC

www.mallinckrodt.com

Latest From Janssen Pharmaceuticals Inc.

Deal Watch: WuXi/Gloria License PD-1 Inhibitor To Arcus For Up To $816m

WuXi Biologics and Harbin Gloria will get $18.5m up front for the Phase I asset GLS-010. Also, Cerecor divests depression drug to Janssen for up to $45m and Perrigo sells its API division for $110m in cash.

Deals Business Strategies

Deals Shaping the Medical Industry, August 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced July 2017.

Deals BioPharmaceutical

Deal Watch: GSK Declines Option As Ionis' Inotersen Nears Finish Line

Ionis will file polyneuropathy candidate in US and EU on its own, while GSK de-emphasizes rare diseases. Aclaris buys Confluence in earn-out-heavy deal, and Galena undertakes reverse merger with Sellas.

Deals M & A

J&J's Symtuza Will Debut In Europe On Cramped HIV Market

Johnson & Johnson's combination HIV therapy Symtuza has secured a greenlight in Europe, marking its first approval worldwide – but will the big pharma be able to catch up with successful HIV opponents from AbbVie and Gilead?

Infectious Diseases Approvals
See All

Company Information

  • Industry
  • Medical Devices
  • Pharmaceuticals
    • Generic Drugs
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Immune Disorders
  • Metabolic Disorders
  • Neurology, Nervous System
  • Renal System
  • Respiratory, Pulmonary
  • Alias(es)
  • Mallinckrodt LLC
  • Mallinckrodt Inc.
  • Mallinckrodt Group, Inc.
  • Mallinckrodt Pharmaceuticals
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • Mallinckrodt PLC
  • Senior Management
  • Mark Trudeau, Pres. & CEO
    Matthew Harbaugh, EVP, CFO
    Gary Phillips, MD, EVP, Chief Strategy Officer
    Steven Romano, MD, EVP, CSO
  • Contact Info
  • Mallinckrodt PLC
    Phone: 17 8463 6700
    3 Lotus Park
    The Causeway
    Staines-Upon-Thames, MO TW18 3AG
    UK
Advertisement
Advertisement
UsernamePublicRestriction

Register